Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim
Information source: University of California, San Francisco
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Severe Combined Immunodeficiency
Intervention: Transplant Conditioning with Mobilization Only (Drug); Transplant Conditioning with Mobilization and Alemtuzumab (Drug)
Phase: Phase 2
Status: Terminated
Sponsored by: University of California, San Francisco Official(s) and/or principal investigator(s): Christopher C Dvorak, M.D., Principal Investigator, Affiliation: University of California, San Francisco
Summary
The goal of this study is to develop a novel approach to hematopoietic stem cell
transplantation for children with Severe Combined Immunodeficiency Disease (SCID) that
eliminates the use of toxic chemotherapy conditioning and maximizes the likelihood of T and
B cell immune reconstitution. Rather than classic chemotherapeutic agents, the investigators
will utilize a targeted stem cell mobilizer, plerixafor, in combination with alemtuzumab, a
monoclonal antibody. Correlative scientific questions will include: 1) efficacy and
characteristics of host stem cell mobilization; and 2) alemtuzumab pharmacokinetics in very
young children.
Clinical Details
Official title: Hematopoietic Stem Cell Transplantation for Children With Severe Combined Immunodeficiency Disease Utilizing Alemtuzumab and Mobilization With Plerixafor & Filgrastim
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Engraftment of Donor B-cells in Blood by STR Testing
Secondary outcome: Incidence of Acute GVHDIncidence of Chronic GVHD Percentage of Patients Who Become Independent From Regular IVIG Infusion Percent Engraftment of Donor Stem Cells in Bone Marrow by STR Testing Percent Engraftment of Donor T-cells in Blood by STR Testing
Detailed description:
The goal of this study is to develop an approach to hematopoietic stem cell transplantation
for children with Severe Combined Immunodeficiency Disease (SCID) that eliminates the use of
toxic chemotherapy conditioning and maximizes the likelihood of T and B cell immune
reconstitution. SCID is a rare primary immunodeficiency disease in which there are multiple
genotypes and phenotypes, and depending on various factors including the presence of B cell
and NK cells, and the presence of maternal cells in the patient's circulation, there are
numerous ways to approach a transplant. The major issues that must be addressed in any
approach to transplantation for SCID are graft rejection and T and B cell immune
reconstitution. Depending on the specific SCID diagnosis, the phenotype, and the presence of
maternal engraftment at diagnosis, we will evaluate two transplant approaches that will
attempt to optimize the engraftment of donor HSC and the likelihood of T and B cell
reconstitution while eliminating the use of toxic chemotherapy conditioning.
1. Primary Objective: To determine if the administration of plerixafor & filgrastim
(G-CSF) prior to stem cell infusion results in increased donor stem cell occupancy of
available bone marrow niches and B-cell engraftment in patients with SCID.
2. Secondary Objectives:
i. To determine if NK cell depletion with Alemtuzumab will overcome NK-mediated graft
resistance in haplocompatible transplants for NK+ SCID.
ii. To determine the optimal dosing of Alemtuzumab in very young children. iii. To determine
the immunophenotypic characteristics of CD34+ cells mobilized and engrafted in patients
receiving plerixafor & filgrastim prior to HCT.
iv. To determine the thymic output, as measured by T-cell receptor excision circles, in
patients receiving haplocompatible transplants & boosts.
Eligibility
Minimum age: N/A.
Maximum age: 3 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients with classic SCID phenotype (<400 CD3/ul or maternally engrafted and <10% of
normal PHA lymphoproliferative response). Genotypic identification is preferable, but
not required.
- Patients must have an acceptable stem cell donor (HLA matched relative, 9 or 10/10
HLA-matched unrelated, or haplocompatible relative).
Exclusion Criteria:
- Patients with "leaky" SCID syndromes, Omenn's Syndrome, reticular dysgenesis, ADA
deficiency
- Lansky score <60%
- Patient with expected survival <4 weeks (including disseminated CMV infection
involving lungs and/or CNS)
Locations and Contacts
UCSF Benioff Children's Hospital, San Francisco, California 94143, United States
Additional Information
UCSF Blood Marrow Transplant Program Website
Related publications: Dvorak CC, Hung GY, Horn B, Dunn E, Oon CY, Cowan MJ. Megadose CD34(+) cell grafts improve recovery of T cell engraftment but not B cell immunity in patients with severe combined immunodeficiency disease undergoing haplocompatible nonmyeloablative transplantation. Biol Blood Marrow Transplant. 2008 Oct;14(10):1125-33. doi: 10.1016/j.bbmt.2008.07.008. Dvorak CC, Cowan MJ. Radiosensitive severe combined immunodeficiency disease. Immunol Allergy Clin North Am. 2010 Feb;30(1):125-42. doi: 10.1016/j.iac.2009.10.004. Dvorak CC, Cowan MJ. Hematopoietic stem cell transplantation for primary immunodeficiency disease. Bone Marrow Transplant. 2008 Jan;41(2):119-26. Epub 2007 Oct 29. Review.
Starting date: August 2010
Last updated: November 6, 2014
|